Fig. 1From: Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover studyScreening, enrollment, and follow-up of the study populationBack to article page